Kilitch Drugs (India) Board of Directors

Get the latest insights into the leadership at Kilitch Drugs (India). Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Mukund P Mehta Managing Director
Mr. Bhavin Mukund Mehta Whole Time Director
Mrs. Mira B Mehta Whole Time Director
Mr. Hemang J Engineer Independent Director
Mr. Venkita Subramanian Rajan Independent Director
Prof. Vasudev Krishna Murti Independent Director

Kilitch Drugs (India) Share price

KILITCH

359.4

3.05 (0.86%)
NSE
BSE
Last updated on 4 Sep, 2025 | 15:31 IST
BUYSELL
Today's High

363.50

Today's Low

356.55

52 Week Low

294.07

52 Week High

500.00

The current prices are delayed, login to your account for live prices

Kilitch Drugs (India) FAQs

The board at Kilitch Drugs (India) consists of experienced professionals, including Mr. Mukund P Mehta , Mr. Bhavin Mukund Mehta , and others, overseeing the company’s strategic and corporate governance.

Directors at Kilitch Drugs (India) are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Mukund P Mehta is the current chairman at Kilitch Drugs (India).

Executive directors at Kilitch Drugs (India) are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Kilitch Drugs (India) adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Kilitch Drugs (India), board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.